tradingkey.logo
tradingkey.logo
検索

Jaguar Health Inc

JAGX
ウォッチリストに追加
0.419USD
+0.019+4.75%
終値 11-13 16:00(ET)
896.66K時価総額
損失額直近12ヶ月PER
時間外取引 19:12 (ET)0.410USD+0.003+0.74%

Jaguar Health Incについて 企業名

Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.

Jaguar Health Inc プロフィール

企業コードJAGX
会社名Jaguar Health Inc
上場日May 13, 2015
最高経営責任者「CEO」Conte (Lisa A)
従業員数49
証券種類Ordinary Share
決算期末May 13
本社所在地200 Pine Street Suite 400
都市SAN FRANCISCO
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号94104
電話番号14153718300
ウェブサイトhttps://jaguar.health/
企業コードJAGX
上場日May 13, 2015
最高経営責任者「CEO」Conte (Lisa A)

Jaguar Health Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Pravin R. Chaturvedi, Ph.D.
Dr. Pravin R. Chaturvedi, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
5.00
--
Mr. Jonathan S. Wolin
Mr. Jonathan S. Wolin
Chief of Staff, General Counsel, Chief Compliance Officer
Chief of Staff, General Counsel, Chief Compliance Officer
4.00
--
Ms. Lisa A. Conte
Ms. Lisa A. Conte
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Steven R. King, Ph.D.
Dr. Steven R. King, Ph.D.
Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property, Secretary
Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property, Secretary
--
--
Mr. James J. Bochnowski
Mr. James J. Bochnowski
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. John J. Micek, III
Mr. John J. Micek, III
Independent Director
Independent Director
--
--
Mr. Jonathan B. Siegel
Mr. Jonathan B. Siegel
Independent Director
Independent Director
--
-100.00%
Ms. Carol R. Lizak
Ms. Carol R. Lizak
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Ian Wendt
Mr. Ian Wendt
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Anula K. Jayasuriya, M.D., Ph.D.
Dr. Anula K. Jayasuriya, M.D., Ph.D.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Pravin R. Chaturvedi, Ph.D.
Dr. Pravin R. Chaturvedi, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
5.00
--
Mr. Jonathan S. Wolin
Mr. Jonathan S. Wolin
Chief of Staff, General Counsel, Chief Compliance Officer
Chief of Staff, General Counsel, Chief Compliance Officer
4.00
--
Ms. Lisa A. Conte
Ms. Lisa A. Conte
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Steven R. King, Ph.D.
Dr. Steven R. King, Ph.D.
Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property, Secretary
Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property, Secretary
--
--
Mr. James J. Bochnowski
Mr. James J. Bochnowski
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. John J. Micek, III
Mr. John J. Micek, III
Independent Director
Independent Director
--
--

よくある質問

Jaguar Health Incの上位5名の株主は誰ですか?

Jaguar Health Incの上位5名の株主は以下のとおりです。Dr. Pravin R. Chaturvedi, Ph.D.

Jaguar Health Inc(JAGX)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Jaguar Health Incの株式を保有している機関は31社あり、保有株式の総市場価値は約4.98Kで、全体の0.83%を占めています。2025Q4と比較して、機関の持ち株は-743.00増加しています。
tradingkey.logo
リスク告知:当社ウェブサイト及びモバイルアプリは特定の投資商品に関する一般的な情報のみを提供しており、Finsightsは金融アドバイスや投資商品の推奨を行うものではありません。本情報の提供をもってFinsightsが投資助言を行っていると解釈されることはありません。
投資商品には元本割れを含む重大なリスクが伴い、全ての投資家に適するものではありません。なお、過去の運用実績は将来の成果を保証するものではありません。
Finsightsは、第三者広告主または提携先が当社ウェブサイト・モバイルアプリ上に広告を掲載することを許可する場合があり、これら広告主から広告への反応に基づく報酬を受けることがあります。
© 著作権: FINSIGHTS MEDIA PTE. LTD. 無断複写・転載を禁じます。